{
    "root": "2fd1d430-a0df-d373-e063-6394a90a622a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Oseltamivir Phosphate",
    "value": "20250308",
    "ingredients": [
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "OSELTAMIVIR PHOSPHATE",
            "code": "4A3O49NGEZ"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": "oseltamivir phosphate capsules influenza neuraminidase inhibitor ( nai ) indicated : treatment acute , uncomplicated influenza b patients 2 weeks age older symptomatic 48 hours . ( 1.1 ) prophylaxis influenza b patients 1 year older . ( 1.2 ) limitations : substitute annual influenza vaccination . ( 1.3 ) consider available information influenza susceptibility patterns treatment effects deciding whether . ( 1.3 ) recommended patients end-stage renal disease undergoing dialysis . ( 1.3 )",
    "contraindications": "treatment influenza adults adolescents ( 13 years older ) : 75 mg twice daily 5 days ( 2.2 ) pediatric patients 1 12 years age : based weight twice daily 5 days ( 2.2 ) pediatric patients 2 weeks less 1 year age : 3mg/kg twice daily 5 days ( 2.2 ) renally impaired adult patients ( creatinine clearance > 30-60 ml/min ) : reduce 30 mg twice daily 5 days ( 2.4 ) renally impaired adult patients ( creatinine clearance > 10-30 ml/min ) : reduce 30 mg daily 5 days ( 2.4 ) esrd patients hemodialysis : reduce 30 mg immediately 30 mg every hemodialysis cycle . treatment duration exceed 5 days ( 2.4 ) esrd patients capd : reduce single 30 mg dose immediately ( 2.4 ) prophylaxis influenza adults adolescents ( 13 years older ) : 75 mg daily least 10 days ( 2.3 ) community outbreak : 75 mg daily 6 weeks ( 2.3 ) pediatric patients 1 12 years age : based weight daily 10 days ( 2.3 ) community outbreak : based weight daily 6 weeks ( 2.3 ) renally impaired adult patients ( creatinine clearance > 30-60 ml/min ) : reduce 30 mg daily ( 2.4 ) renally impaired adult patients ( creatinine clearance > 10-30 ml/min ) : reduce 30 mg every day ( 2.4 ) esrd patients hemodialysis : reduce 30 mg immediately 30 mg alternate hemodialysis cycles recommended duration prophylaxis ( 2.4 ) esrd patients capd : reduce 30 mg immediately 30 mg weekly recommended duration prophylaxis ( 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "oseltamivir phosphate capsules contraindicated patients known serious hypersensitivity oseltamivir component product . severe allergic included anaphylaxis serious skin including toxic epidermal necrolysis , stevens-johnson syndrome , erythema multiforme [ ( 5.1 ) ] .",
    "indications_original": "Oseltamivir phosphate capsules are\u00a0influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 )",
    "contraindications_original": "Treatment of influenza Adults and adolescents (13 years and older): 75 mg twice daily for 5 days ( 2.2 ) Pediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days ( 2.2 ) Pediatric patients 2 weeks to less than 1 year of age: 3mg/kg twice daily for 5 days ( 2.2 ) Renally impaired adult patients (creatinine clearance >30-60 mL/min): Reduce to 30 mg twice daily for 5 days ( 2.4 ) Renally impaired adult patients (creatinine clearance >10-30 mL/min): Reduce to 30 mg once daily for 5 days ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle. Treatment duration not to exceed 5 days ( 2.4 ) ESRD patients on CAPD: Reduce to a single 30 mg dose immediately ( 2.4 ) Prophylaxis of influenza Adults and adolescents (13 years and older): 75 mg once daily for at least 10 days ( 2.3 ) Community outbreak: 75 mg once daily for up to 6 weeks ( 2.3 ) Pediatric patients 1 to 12 years of age: Based on weight once daily for 10 days ( 2.3 ) Community outbreak: Based on weight once daily for up to 6 weeks ( 2.3 ) Renally impaired adult patients (creatinine clearance >30-60 mL/min): Reduce to 30 mg once daily ( 2.4 ) Renally impaired adult patients (creatinine clearance >10-30 mL/min): Reduce to 30 mg once every other day ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after alternate hemodialysis cycles for the recommended duration of prophylaxis ( 2.4 ) ESRD patients on CAPD: Reduce to 30 mg immediately and then 30 mg once weekly for the recommended duration of prophylaxis ( 2.4 )",
    "adverseReactions_original": "Oseltamivir phosphate capsules are\u00a0contraindicated in patients with known serious hypersensitivity to oseltamivir or any component of the product. Severe allergic reactions have included anaphylaxis and serious skin reactions including toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme\n \n  [see\n  \n   Warnings and Precautions (5.1)]\n \n  ."
}